BioCentury This Week

This BioCentury podcast episode covers surging China pharma partnerships with larger and earlier-stage deals, allegations of trade secret theft in the Beam v. Yoltec case, the Trump administration's significantly scaled-back GLOBE drug pricing model, and the Nobel Prize in Physiology or Medicine awarded for optogenetics research.

BioCentury's Grand Rounds Europe conference in Amsterdam gathered biotech leaders to discuss emerging therapeutic mechanisms, the role of fundamental biology in drug discovery, and the importance of entrepreneurship in European biotech. Key themes included the potential of GLP-1 successors, aging biology, the risks of over-complex molecular constructs, and the need for hypothesis-driven science over permutation testing.

This BioCentury podcast episode covers three major topics: the rapid advancement of IgA nephropathy drug development driven by academic discovery and FDA guidance, FDA Commissioner nominee Heidi Overton's confirmation hearing where she emphasized speed and vaccine safety, and the growing popularity of reverse mergers with concurrent PIPE financing as an alternative to traditional IPOs for biotech companies.

Episode 388 covers three major biotech topics: Electra's biotech IPO upsized but fell 12% on its first trading day, marking an end to a winning streak; fatal toxicities in Novartis' autoimmune CAR-T trial raise safety concerns across the sector; and pharma tariffs set for September 29th lack clear implementation guidance, disproportionately affecting small and mid-sized companies.

Novartis experienced three major clinical trial failures in one week, wiping out $40 billion in market cap, with the most significant being the failed Phase 3 for Pellicarson (anti-LP(a) antisense therapy). The episode discusses potential explanations for the failure and broader implications for RNA therapeutics and cardiovascular drug development, while also covering pharma M&A trends showing increased focus on disruptive technologies and rising China biotech partnerships.

Novartis suffered three major clinical trial failures in one week, losing $40 billion in market cap, particularly from the failed LP(a)-targeting antisense therapy Pelacarsen, raising questions about the molecule, target, and timing of intervention. Pharma companies are increasingly embracing disruptive technologies like bispecifics, in vivo CAR-Ts, and siRNAs through licensing deals and M&A, with Eli Lilly leading dealmaking activity; meanwhile, the Trump administration is pressuring mid-tier U.S. biotechs to sign Most Favored Nation drug pricing agreements with unclear terms.

This BioCentury podcast episode covers three major healthcare policy developments: the Trump administration's Most Favored Nation (MFN) drug pricing deals with 17 pharmaceutical companies, Eli Lilly's $2.9 billion acquisition of Merida for autoimmune disease therapeutics, and the nomination of Heidi Overton as FDA commissioner, alongside RevMed's rapid FDA approval for a pancreatic cancer therapy.

This special BioCentury podcast episode examines global reforms to accelerate first-in-human (FIH) clinical trials, analyzing how China's speed has prompted regulatory changes across the US, Australia, Europe, and Asia. The discussion reveals that success depends less on geopolitics and more on rethinking risk management paradigms, with 73% convergence on specific reforms across major proposals, though implementation varies significantly by jurisdiction.

BioCentury discusses Moderna's major Phase 3 win with Merck in personalized neoantigen vaccines for melanoma, Genentech-Roche's obesity deal with Korean company Hanmi for a urocortin-2 analog, and concerns about FDA independence following the nomination of Trump loyalist Heidi Overton as FDA commissioner.